CGEM - Cullinan Oncology, Inc.
IEX Last Trade
11.98
-0.290 -2.421%
Share volume: 0
Last Updated: Thu 26 Dec 2024 03:30:18 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
3.82%
PREVIOUS CLOSE
CHG
CHG%
$12.27
-0.29
-2.36%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
5.78%
1 Month
-2.15%
3 Months
-24.91%
6 Months
-25.27%
1 Year
29.84%
2 Year
26.23%
Key data
Stock price
$11.98
DAY RANGE
N/A - N/A
52 WEEK RANGE
$10.29 - $30.19
52 WEEK CHANGE
$22.09
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Nadim Ahmed
Region: US
Website: cullinanoncology.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: cullinanoncology.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Cullinan Oncology Inc. focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer.
Recent news